Radiation exposure in90Y-Zevalin therapy: Results of a prospective multicentre trial;Strahlenexposition bei der90Y-Zevalin-therapie: Ergebnisse einer prospektiven multizentrischen studie

NuklearMedizin

Volumn 45, Issue 2, 2006, Pages 82-86

  Geworski, Lilli ^a   Zophel K ^b   Rimpler, A ^c   Barth, I ^c   Lassmann, M ^d   Sandrock, D ^a   Zander, A ^a   Halm, T ^b   Hanscheid H ^d   Hofmann, M ^e   Reiners, Chr ^d   Munz, D L ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b KLINIKUM CHEMNITZ   (Germany)

^c BUNDESAMT FÜR STRAHLENSCHUTZ   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e UNIVERSITY OF BERN   (Switzerland)

Author keywords

90Y; Bremsstrahlung; Ibritumomab tiuxetan; Radiation exposure; Radiation protection; Radioimmunotherapy; Skin dose; Zevalin; rays

Indexed keywords

IBRITUMOMAB TIUXETAN; YTTRIUM 90; MONOCLONAL ANTIBODY; YTTRIUM;

ARTICLE; CONTROLLED STUDY; DOSIMETER; HUMAN; NUCLEAR MEDICINE; OUTPATIENT; PHYSICIAN; RADIATION DOSE; RADIATION EXPOSURE; RADIATION PROTECTION; RADIOCHEMISTRY; RADIOIMMUNOTHERAPY; URINE; CLINICAL TRIAL; FINGER; METABOLIC CLEARANCE RATE; MULTICENTER STUDY; PROSPECTIVE STUDY; SKIN;

ANTIBODIES, MONOCLONAL; FINGERS; HUMANS; METABOLIC CLEARANCE RATE; PROSPECTIVE STUDIES; RADIOIMMUNOTHERAPY; RADIOTHERAPY DOSAGE; SKIN; YTTRIUM RADIOISOTOPES;

EID: 33646102221     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1625737     Document Type: Article

References (14)

1. Delacroix D, Guerre JP, Leblanc P et al. Radionuclide and radiation protection data handbook 2nd ed. Radiat Prot Dosimetry 2002; 98: 9-168.
2. + follicular B-cell non-Hodgekin's lymphoma. Nuklearmedizin 2004; 43: 171-6.
3. 90Y-ibritumomab tiuxetan in clinical practice. Leuk Lymphoma 2003; 44 (Suppl): S37-47.
4. ICRP. Recommendations of the ICRP. ICRP Publication 60. Ann of the ICRP, 21(1-3). Oxford: Pergamon Press, 1991.
5. 90Y. Diplomarbeit, Fachhochschule Gießen-Friedberg 2003, http://info.bib.fh-giessen.de/opus/volltexte/2003/174.
6. Staak JO, Dietlein M, Engert A et al. Hodgkin's lymphoma in nuclear medicine: diagnostic and therapeutic aspects. Nuklearmedizin 2003; 42: 19-24.
7. 90Y-markiertem Ibritumomab-Tiuxetan (Zevalin®): Klinik, Radiopharmazie, Strahlenschutz, Perspektiven. Nuklearmedizin 2005; 44: 166-77.
8. Verordnung über den Schutz vor Schäden durch ionisierende Strahlen (Strahlenschutzverordnung - StrlSchV). Bundesgesetzblatt, Teil I, Nr. 38 vom 20.07.2001.
9. 90Y-labeled anti-CD20 monoclonal antibody. J Nucl Med 2002; 43: 267-72.
10. Wiseman GA, Gordon LI, Multani PS et al. Ibritumomab tiuxetan radioimmunotherapyfor patients with relapsed or refractory non-Hodgkin Lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 89: 4336-42.
11. Wiseman GA, Leigh BR, Raubitzchek A et al. Urinary clearance of yttrium-90 activity following Zevalin radioimmunotherapy of B-Cell non-Hodgkin's lymphoma. J Nucl Med 2001; 42: 268.
12. Wiseman GA, Leigh BR, Witzig T et al. Radiation exposure is very low to the family members of patients treated with yttrium-90 zevalin anti-CD20 monoclonal antibody therapy for lymphoma. Eur J Nucl Med 2001; 28: 1198.
13. Wiseman GA, White CA, Sparks RB et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin® radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 2001; 39: 181-94.
14. Witzig TE, Gordon LI, Cabanillas F. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453-63.